Functional analysis of CD109 in Brain Tumor.

2020 Fiscal Year Final Research Report

• Project/Area Number: 18K15116
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 49030:Experimental pathology-related
• Research Institution: Nagoya University
• Principal Investigator: Shiraki Yukihiro 名古屋大学, 医学系研究科, 助教 (40804753)
• Project Period (FY): 2018-04-01 – 2021-03-31
• Keywords: CD109

Outline of Final Research Achievements

We identified latent TGF-β binding protein-1 (LTBP1) as a CD109-interacting protein using mass spectrometry and confirmed their interaction by co-immunoprecipitation. CD109 expression enhanced TGF-β activation in the presence of LTBP1.
Although we tried to develop antibody drug against CD109, we could not obtain notarizing antibody or antibody with ADCC activity.

Free Research Field

実験病理

Academic Significance and Societal Importance of the Research Achievements

CD109は様々な腫瘍で悪性化・進展に関わる分子であるが、今回新たにCD109がLTBP1に対して結合して、TGF-β活性化を促進するという機能を発見した。CD109を発現する腫瘍細胞と周囲の微小環境との関りを研究する上で重要な知見が得られたと考えている。